QUESTION 13

1.      A patient with schizophrenia is given an inverse agonist that acts on the receptor 5HT and neurotransmitter serotonin. What is the rationale for prescribing a medication such as this?

A.

To promote the availability of serotonin

B.

To decrease serotonin

C.

To indirectly increase the amount of dopamine in the body

D.

To help decrease the amount of serotonin and dopamine

1 points  

QUESTION 14

1.      The PMHNP is caring for four patients. Which patient statement indicates that benzodiazepines would be beneficial?

A.

“I have trouble staying asleep in the middle of the night.”

B.

“My spouse told me that I seem to have trouble remembering things sometimes.”

C.

“I really want to stop smoking, but the cravings are too strong.”

D.

“I feel nervous to go outside and be in large crowds.”

1 points  

QUESTION 15

1.      Ms. Harlow is a 42-year-old patient who is prescribed a drug that acts on ionotropic receptors. She is curious about the effects of the drug and how it will act on her symptoms. Which statement made by the PMHNP demonstrates proper understanding of Ms. Harlow’s prescription?

A.

“The drug will have an almost immediate effect.”

B.

“The drug can take a while to build up in your system.”

C.

“The drug is slow to release but lasts for a long time.”

D.

“The drug will make a subtle difference in your symptoms.”

1 points  

QUESTION 16

1.      A patient is seeking pharmacological treatment for smoking cessation. Which drug class does the PMHNP prescribe to the patient?

A.

Benzodiazepine

B.

Mirtazapine (Remeron)

C.

Ketamine

D.

Varenicline (Chantix)

1 points  

QUESTION 17

1.      The PMHNP is caring for a new patient who has been transferred from another office. When meeting with the new patient, the patient reports, “I feel like I am improving with the stabilizers.” The PMHNP immediately recognizes that the patient is describing which kind of drug?

A.

Full agonists

B.

Antagonists

C.

Partial agonists

D.

Inverse agonists

1 points  

QUESTION 18

1.      A patient presents with frequent episodes of mania. Which statement describes an appropriate treatment approach for this patient?

A.

“The patient needs to have an inverse agonist.”

B.

“The patient could benefit from an anticonvulsant.”

C.

“The patient’s calcium, sodium, chloride, and potassium levels must be regulated.”

D.

“The patient should have a drug that acts on ligand-gated ion channels.”

1 points  

QUESTION 19

1.      The PHMNP is caring for a patient who would benefit from nicotine cholinergic, serotonin 3, or glycine receptors. What kind of agent does the PHMNP want to prescribe for this patient?

A.

Ligand-gated ion channels with a pentameric structure

B.

Ligand-gated ion channels with a tetrameric structure

C.

Voltage-sensitive ion channels

D.

Anticonvulsants

1 points  

QUESTION 20 ?

1.      Which statement made by the patient suggests the patient will need to be treated with antipsychotics that target paranoid psychosis?

A.

“It’s my fault that all of this is happening. I don’t think I could ever forgive myself.”

B.

“I have to talk to the President because I’m the only one who can help him.”

C.

“I’m not sure why that lady is wearing a red jacket since it’s the dogs who need food.”

D.

“I don’t know that I even want to go to that meeting. It doesn’t seem worth it anymore.”

1 points  

QUESTION 21

1.      A patient has been treated with a number of novel psychotropic drugs. How is it theoretically possible to identify cognitive improvement in the patient using neuropsychological assessment batteries after the pharmacologic therapy? I did not have this question

A.

Obtaining raw normative metrics and using them to assess functionality

B.

Having the patient report on cognitive function based on personal experiences

C.

Monitoring the patient in a controlled setting

D.

Measuring symptoms of psychosis

1 points  

QUESTION 22

1.      Mr. McCullin is 64 years old with Parkinson’s disease. The PMHNP caring for Mr. McCullin wants to start him on a dopamine agonist to help manage and treat his condition. The PHMNP selects this agent because of which action it has on patients like Mr. McCullin?

A.

Dopamine is terminated through multiple mechanisms.

B.

The D2 autoreceptor regulates release of dopamine from the presynaptic neuron.

C.

MAO-B presents in the mitochondria within the presynaptic neuron.

D.

D2 receptors are the primary binding site for dopamine agonists.

1 points  

QUESTION 23

1.      Mrs. Trevor is a 44-year-old patient who does not have a diagnosis of schizophrenia but occasionally reports symptoms of psychosis, followed by severe fatigue. Mrs. Trevor inquires about the use of amphetamines to help with her energy levels. Which response made by the PMHNP is most appropriate?

A.

“Amphetamines may help you, as they can alleviate psychotic conditions.”

B.

“Amphetamines can inhibit negative symptoms of schizophrenia, so this might be a good choice for you.”

C.

“Amphetamines can cause hallucinations, so I would advise against this type of prescription.”

D.

“Amphetamines can lead to a dopamine deficiency, so I will not prescribe this for you.”

1 points  

QUESTION 24

1.      The PMHNP is caring for a patient with schizophrenia and is considering a variety of treatment approaches. The PHMNP selects a viable treatment that is consistent with the “dopamine hypothesis of schizophrenia.” What action does the PMHNP anticipate this treatment having on the patient?

A.

Blocking the release of dopamine facilitates the onset of positive schizophrenia symptoms.

B.

Hyperactivity in the mesolimbic dopamine pathway mediates the positive symptoms of schizophrenia.

C.

Antipsychotic drugs that open D2 receptor pathways can treat schizophrenia.

D.

The neuroanatomy of dopamine neuronal pathways can explain symptoms of schizophrenia.

1 points